Dr. Reddy's Laboratories acquires Preferred A-1 shares of Edity Therapeutics
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
MedTech Mitra is a platform that will help the young talents of the country by holding their hands and giving them final shape to their research, knowledge and logic
Furthering cell therapy ambition across oncology and autoimmune diseases
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Subscribe To Our Newsletter & Stay Updated